Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT04363567 Completed - Healthy Clinical Trials

Endothelial Glycocalyx in Patients With Chronic Kidney Disease

EGNI
Start date: November 7, 2016
Phase:
Study type: Observational

The luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (EG). EG is important for the transport of molecules in and out of the blood cells and for endothelial function. EG protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. Overall it is likely to avoid development of cardiovascular disease. A newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of EG. EG can also be measured by release of endothelial glycocalyx proteins. Previous studies indicate that this EG is impaired by a number of chronic diseases, including chronic kidney disease. This study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.

NCT ID: NCT04363554 Completed - Clinical trials for Chronic Kidney Diseases

The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease

POVA
Start date: September 25, 2017
Phase: N/A
Study type: Interventional

The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct. Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the formation of cyst in the kidneys, causing gradual renal function-loss. Previous studies indicate that ADPKD patients have decreased urine concentration, higher plasma osmolality, and plasma AVP levels compared to healthy controls. Previous studies also indicate that ADPKD patients' dysregulated AVP is an important factor for the pathogenesis and progression of the disease. It is unclear whether ADPKD patients' ability to concentrate and dilute urine are different from those of other cause of chronic renal disease to the same degree. It is also unclear, what mechanisms cause the decreased ability to concentrate and dilute urine in chronic renal disease patients. The purpose of this trial is to investigate the difference in renal function during concentration and dilution test in a case-control, randomized, cross-examination study with ADKPD patients or other cause of chronic renal disease compared to healthy volunteers.

NCT ID: NCT04361097 Completed - Clinical trials for Chronic Kidney Disease Due to Type 2 Diabetes Mellitus

Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease

Start date: August 7, 2018
Phase: N/A
Study type: Interventional

What the investigators want to achieve with the protocol is to identify the impact of intestinal microbiota transplantation on the progression of chronic kidney disease. Hypothesis: Modification of intestinal microbioma of CKD patients by TMF decrease the progression of CKD Methodological design: Experimental, prospective, double-blind. Inclusion criteria: Being diagnosed with CKD and creatinine clearance less than 60 mL/minute secondary hypertension and/or diabetes and older than 18 years

NCT ID: NCT04350944 Completed - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

FGF-23 and PTH in Hemodialysis Patients

Start date: January 14, 2020
Phase:
Study type: Observational [Patient Registry]

In this pilot study the investigator will examine the levels of fibroblast growth factor (FGF-23) and parathyroid hormone (PTH) levels during hemodialysis therapy in 30 patients and assess the correlation between these parameters and the T-50 calcification propensity, as well as further parameters of secondary hyperparathyroidism (sHPT), like serum calcium (sCa), phosphate (P), 25-hydroxy-vitamin D (25(OH)D) and 1,25 dihydroxy-vitamin D (1,25(OH)2D). The investigator hypothesize that FGF-23 and PTH levels are at their highest at the beginning of dialysis and decrease during the treatment.

NCT ID: NCT04336566 Completed - Clinical trials for Chronic Kidney Diseases

Renal Effects of Melatonin Trial in Chronic Kidney Disease

REM
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

This will be a prospective, double blinded, randomized, controlled pilot study to determine if there is any correlation between melatonin administration and proteinuria.

NCT ID: NCT04312295 Completed - Clinical trials for Chronic Kidney Diseases

ACP Simulation-based Communication Training Program for Nurses Discussing ACP With Chronic Kidney Disease Patients

Start date: September 19, 2019
Phase: N/A
Study type: Interventional

This study was to evaluate the effects of ACP simulation-based communication training program (ACP-SCT program) for nurses to discuss ACP with chronic kidney disease patients

NCT ID: NCT04289038 Completed - Pruritus Clinical Trials

The Efficacy of VR and AR on Pruritus

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The research will be conducted randomly in order to determine the effect of VR and AR on pruritus symptom.

NCT ID: NCT04256629 Completed - Clinical trials for Healthy Volunteers (Intended Indication: Chronic Kidney Disease)

A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart

Start date: March 3, 2020
Phase: Phase 1
Study type: Interventional

This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval

NCT ID: NCT04226443 Completed - Clinical trials for Chronic Kidney Diseases

The Use of Midazolam and Remifentanil During Dialysis Access Procedures

Start date: August 28, 2012
Phase: N/A
Study type: Interventional

BACKGROUND: Sedation and analgesia are related to unexpected adverse events in chronic renal failure patients undergoing arteriovenous fistula placement procedures under monitored anesthesia care (MAC). OBJECTIVE: Our goal was to investigate and compare the sedation and analgesia related effects and adverse effects of continuous intravenous use of midazolam and intermittent bolus doses of midazolam while intravenous remifentanil is used as a rescue medication in patients with chronic renal failure.

NCT ID: NCT04222153 Completed - Healthy Clinical Trials

Innovative Approach to Fecal Microbiota Transplantation (FMT) Applied for Chronic Kidney Disease (CKD)

Start date: November 26, 2019
Phase:
Study type: Observational

The aim of this PhD project focuses on the relationship between intestinal microbiota and health in the background of Chronic Kidney Disease (CKD). Many pathologies, including the CKD, display a dysbiosis of the intestinal microbiota, which is at the same time a consequence of CKD and contributes to its progression and complication. In a variety of chronic-degenerative and infectious diseases, the "fecal microbiota transplantation" (FMT) is being tested in recent years in addition with the application of both probiotics and prebiotics. FMT is indeed currently successfully used in the eradication of recurrent Clostridium difficile infections, with success rates of 90%, thus recent evidence suggests that FMT could be applied in other diseases characterized by microbiota dysbiosis, such as CKD and diabetes, in which the FMT has never been previously tested. This project will allow to study: i) the prototypal production of the encapsulated suspension of healthy microbiota tested in a minimally invasive FMT procedure (by oral administration); ii) the efficacy of the innovative prototype for colonization and modulation of intestinal microbiota following FMT; iii) the experimental and clinical feedback of this suspension, by in vivo studies.